Evidence-based clinical guidelines provide standards for the provision of healthcare. However, these guidelines have been poorly implemented in daily practice. Clinical audit is a quality improvement tool to promote quality of care in daily practice and to improve outcomes through the systematic review of care delivery and implementation of changes. A major priority in the management of subjects with cardiovascular disease (CVD) management is secondary prevention by controlling cardiovascular risk factors and providing appropriate medical treatment. Clinical audits can be applied to monitor modifiable risk factors and evaluate quality improvements of CVD management in daily practice. Existing clinical audits have provided an overview of the burden of risk factors in subjects with CVD and reflect real-world risk factor recording and management. However, consistent and representative data from clinic audits are still insufficient to fully monitor quality improvement of CVD management. Data are lacking in particular from low-and middle-income countries, limiting the evaluation of CVD management quality by clinical audit projects in many settings. To support the development of clinical standards, monitor daily practice performance, and improve quality of care in CVD management at national and international levels, more widespread clinical audits are warranted.
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This requires health professionals and providers to adhere to structured standards of care, monitor routine healthcare performance, and reduce inequalities in patient management. [1] [2] [3] Evidence-based clinical guidelines provide standards for the provision of healthcare. They should reflect the conscientious, explicit and judicious use of current best evidence in decision making and in delivering optimal care management strategies for individual patients. 4 Quality of care can then be quantified and measured against these established clinical guidelines to assess both health outcomes and performance of healthcare providers.
However, the availability of guidelines does not necessarily ensure a high standard of clinical care. Nor do they assure the monitoring of the quality of care on a daily basis. Striking disparities and inequities in routine patient management have been recognised as a fundamental issue in healthcare performance regardless of strong recommendations from clinical guidelines. 5, 6 A significant number of patients do not receive evidence-based care as suggested for their health conditions in terms of risk factor management, and globally the quality of patient care is still poor. 7, 8 Thus, one of the key components in current healthcare settings should be implementation and evaluation of standardised care and assessment of health outcomes to ensure that high-quality care is provided to patients in daily practice.
9,10

Introduction of clinical audits
A clinical audit is defined as a quality improvement cycle that involves measurement of the effectiveness of healthcare against agreed and proven standards for high-quality care, and corrective action to bring practice in line with these standards so as to improve the quality of care and health outcomes (Figure 1 ).
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Clinical audits allow valuable comparative information on local, national or international levels to be obtained so that institutions and clinicians can compare and share this information. They can also measure changes in health outcomes over time and to what extent these changes are sustained in the long term. 11, 12 Four essential stages are required for a good-quality clinical audit:
. audit preparation and planning; . implementation to measure quality of care;
. implementation of changes in line with best practice guidelines; . re-audit to sustain quality improvement.
In each cycle, clinical audits provide an objective assessment of defined outcomes and information on the process of care and the extent to which daily practice is being implemented according to defined standards. The re-audit activity facilitates the regular monitoring of healthcare performance and the evaluation of improvements of quality of care in daily practice.
Given Similarly, prospective observational studies with a focus on quality assurance of healthcare could also be considered as audits.
International clinical audits of cardiovascular disease management
Clinical audit can be performed in a number of areas relevant to cardiovascular disease (CVD) management, and the intentions of clinical audits can be interpreted in different ways to monitor whether quality of care has been improved. Thus, the study design can vary from study to study. In the current literature review, we selected as examples five international studies with different study designs to give a broad description of current audit programmes running for cardiovascular risk factor management ( Table 1) . One study was performed as a clinical audit during routine practice, 13, 14 while others were applied as registries [15] [16] [17] or crosssectional surveys. [18] [19] [20] [21] [22] A large-scale prospective cohort study 23, 24 was also identified as an example that aimed to assess lifestyle risk factor management and cardiovascular medication use for CVD secondary prevention.
The findings of these five studies are broadly similar irrespective of their study design and the time frame of data collection. They all demonstrated that the current management of modifiable cardiovascular risk factors and medical treatments is still insufficient, with substantial variations at country and regional levels. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The presence of ongoing smoking, obesity and diabetes remains a major problem.
13-24
EUROASPIRE
The European Society of Cardiology developed the European Action on Secondary Primary Prevention by Intervention to Reduce Events (EUROASPIRE) survey to measure modifiable risk factor and therapeutic management in coronary heart disease (CHD) patients and to monitor the quality of secondary prevention care provided by individual participating countries. 18 EUROASPIRE is a European-based cross-sectional survey, conducted in four different time frames: 1995-1996 in 9 European countries (EUROASPIRE I), (EUROASPIRE III) 20 and 2012-2013 in 24 European countries (EUROASPIRE IV). 21 EUROASPIRE data, collected by means of a faceto-face interview with standardised measurement of risk factors rather than from review of medical records, provide high-quality comparative information on preventive care. In addition, four EUROASPIRE surveys with a uniform collection method from the same participating centres allow multilevel comparison to evaluate any potential trends in CHD management over years. [25] [26] [27] EUROASPIRE has major strengths in terms of highly standardised methods and centralised laboratory measurements. However, its detailed protocol requires considerable resources from participating centres in terms of cost and time. These factors and the low interview rate (<50%) arising may limit generalisability of the results to whole populations. Non-participants may be more likely to have poor CHD management. 21 The robust methodology should encourage efforts to apply EUROASPIRE to more centres in participating countries to increase representativeness, but costs may be prohibitive.
SURF
The SUrvey of Risk Factor Management (SURF) was developed by the European Association of Preventive Cardiology, aiming to investigate daily data recording and assess cardiovascular risk factor management in routine clinics. SURF was first tested for feasibility as a pilot study in seven countries 13 and the first phase (SURF I) in 11 countries. 14 SURF uses a one-page data sheet that can easily be collected during a routine clinic visit rather than requiring detailed examinations of patients or retrieving information from medical records. Its simplicity allows applicability to smaller centres with limited resources as well as major academic centres in Europe and beyond to monitor quality of care in daily practice with minimal workload and cost. It also allows regular re-audits to evaluate changes in cardiovascular risk factor management. Limitations to date include nonrepresentativeness of participating centres in SURF countries. Following SURF I, SURF II is planned in mid-2017 with a wider and larger range of participating centres.
WHO-PREMISE
The WHO Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE) study was carried out between 2002 and 2003 in 10 countries. 22 The WHO-PREMISE study was one of the largest descriptive cross-sectional surveys in low-and middle-income countries to assess the current secondary prevention strategy for CVD and record the use of cardiovascular medications. It also documented patients' attitude and knowledge towards CVD prevention management, demonstrating the necessity for cardiovascular education programmes.
As data were collected by self-reported questionnaire, response bias may have occurred, limiting generalisability, even though a face-to-face interview was applied to minimise missing or incorrect information. The second and third phases of the WHO-PREMISE study are planned to implement evidence-based, affordable and sustainable interventions for secondary prevention of CVD both in the demonstration areas and nationally.
REACH registry
The Reduction of Atherothrombosis for Continued Health (REACH) Registry was developed in 44 countries across six regions between 2003 and 2004 to evaluate cardiovascular risk factor prevalence and medical treatment management of cerebrovascular, arterial, or peripheral arterial disease. [15] [16] [17] The REACH registry extended its data collection beyond CHD to stroke and peripheral arterial disease with detailed follow-up information on reoccurrence of cardiac events to investigate the possible contribution of cardiovascular risk factors to all types of vascular diseases. Furthermore, the REACH registry is more geographically diverse than the other audits considered here, which may improve representativeness. It is somewhat dated, and it is hoped that the follow-up phase will incorporate more diverse geographic areas.
PURE
The Prospective Urban Rural Epidemiology (PURE) study is a large-scale community-based prospective cohort study conducted since 2003 in 17 countries. 23, 24 One of the main purposes is to document the use of guideline-recommended cardiovascular medication and prevalence of modifiable risk factors in patients with established CVD. The PURE study can be considered partly as an audit, as it is used to assess quality of secondary prevention care in CVD management.
The unique sampling process enabled data collection from communities in both urban and rural areas to identify all traditional risk factors as well as societal and environmental determinants of CVD. These new and valuable data will provide policy makers with information to develop more efficient and comprehensive CVD prevention programmes. The detailed examination and annual follow-up allow documentation of all potential disease events and monitoring of the control of cardiovascular risk factors. However, as a prospective cohort study, PURE is facing challenges to maintaining good-quality data and a high response rate over time to guarantee its long-term monitoring of CVD management.
National clinical audits in coronary heart disease management Clinical audits have also been introduced at national level in several countries. Evidence from the United Kingdom, 28, 29 Australia, 30 Sweden, 31 Spain 32 and Croatia 33 showed that clinical audit projects can be an effective tool to assist health professionals to monitor and improve the quality and outcomes of their local services. For instance, the Action on Secondary Prevention through Intervention to Reduce Events (ASPIRE-2-PREVENT) survey in the United Kingdom was developed to determine whether CVD guidelines have been implemented properly and enable quality of care to be accessed in everyday practice. 28 
Challenges on clinical audit projects
The above-quoted studies provide examples of the use of audits to monitor quality of care and give insight into daily practice of current CVD management. Prospective observational studies have indicated that the audit programmes could improve quality of care and achieve better modifiable risk factor managements than usual care alone over time. [25] [26] [27] 30 However, there is a lack of randomised controlled trials to provide evidence of a reduction in hard CVD end points as a result of clinical audits. The quality of the audits reviewed varied, and consistent and representative data at international or national level are still lacking, indicating that the potential for quality improvement of CVD management has not been fulfilled. Furthermore, there is also a striking dearth of data from low-and middle-income countries, which have not yet conducted any clinical audits to evaluate their CVD management quality. This is of concern, since resource constraints may make the delivery of high-quality care even more challenging. It points to the need to promote simple audits with wider representativeness to facilitate healthcare improvements worldwide. Thus, a successful clinical audit programme of CVD prevention in daily practice should contain these features:
. simple but structured methodology; . repeatability; . adaptability; . representativeness; . multiple levels (local, national or international).
Conclusion
Clinical audit enables both the recording and the monitoring of cardiovascular risk factors to facilitate guideline-based standard operating procedures to improve clinical practice. Good-quality clinical audit is still lacking. More highly standardised clinical audits are warranted to support the development of clinical standards, monitor daily practice performance, and improve quality of care in CVD management.
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